LIF-IGF Axis Contributes to the Proliferation of Neural Progenitor Cells in Developing Rat Cerebrum

Int J Mol Sci. 2022 Oct 30;23(21):13199. doi: 10.3390/ijms232113199.

Abstract

In rodent models, leukemia inhibitory factor (LIF) is involved in cerebral development via the placenta, and maternal immune activation is linked to psychiatric disorders in the child. However, whether LIF acts directly on neural progenitor cells (NPCs) remains unclear. This study performed DNA microarray analysis and quantitative RT-PCR on the fetal cerebrum after maternal intraperitoneal or fetal intracerebral ventricular injection of LIF at day 14.5 (E14.5) and determined that the expression of insulin-like growth factors (IGF)-1 and -2 was induced by LIF. Physiological IGF-1 and IGF-2 levels in fetal cerebrospinal fluid (CSF) increased from E15.5 to E17.5, following the physiological surge of LIF levels in CSF at E15.5. Immunostaining showed that IGF-1 was expressed in the cerebrum at E15.5 to E19.5 and IGF-2 at E15.5 to E17.5 and that IGF-1 receptor and insulin receptor were co-expressed in NPCs. Further, LIF treatment enhanced cultured NPC proliferation, which was reduced by picropodophyllin, an IGF-1 receptor inhibitor, even under LIF supplementation. Our findings suggest that IGF expression and release from the NPCs of the fetal cerebrum in fetal CSF is induced by LIF, thus supporting the involvement of the LIF-IGF axis in cerebral cortical development in an autocrine/paracrine manner.

Keywords: cerebrum; insulin-like growth factor 1; insulin-like growth factor 2; leukemia inhibitory factor; maternal immune activation; neural progenitor cell; neurogenesis; psychiatric disorders.

MeSH terms

  • Animals
  • Cell Proliferation
  • Cerebrum* / metabolism
  • Female
  • Insulin-Like Growth Factor I / metabolism
  • Insulin-Like Growth Factor II / metabolism
  • Leukemia Inhibitory Factor* / metabolism
  • Neural Stem Cells* / metabolism
  • Pregnancy
  • Rats
  • Receptor, IGF Type 1 / metabolism
  • Somatomedins*

Substances

  • Insulin-Like Growth Factor I
  • Insulin-Like Growth Factor II
  • Leukemia Inhibitory Factor
  • Receptor, IGF Type 1
  • Somatomedins

Grants and funding

This work was supported by KAKENHI (Grant Number K2020-19, 16H05364, 15K15405, 19K22696).